Zevra Therapeutics (ZVRA) Competitors $11.56 +0.01 (+0.09%) Closing price 04:00 PM EasternExtended Trading$11.69 +0.13 (+1.12%) As of 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZVRA vs. VCEL, AGIO, CGON, KNSA, BEAM, IDYA, IRON, BLTE, CNTA, and HRMYShould you be buying Zevra Therapeutics stock or one of its competitors? The main competitors of Zevra Therapeutics include Vericel (VCEL), Agios Pharmaceuticals (AGIO), CG Oncology (CGON), Kiniksa Pharmaceuticals International (KNSA), Beam Therapeutics (BEAM), IDEAYA Biosciences (IDYA), Disc Medicine (IRON), Belite Bio (BLTE), Centessa Pharmaceuticals (CNTA), and Harmony Biosciences (HRMY). These companies are all part of the "pharmaceutical products" industry. Zevra Therapeutics vs. Its Competitors Vericel Agios Pharmaceuticals CG Oncology Kiniksa Pharmaceuticals International Beam Therapeutics IDEAYA Biosciences Disc Medicine Belite Bio Centessa Pharmaceuticals Harmony Biosciences Vericel (NASDAQ:VCEL) and Zevra Therapeutics (NASDAQ:ZVRA) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability and valuation. Which has more risk & volatility, VCEL or ZVRA? Vericel has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500. Comparatively, Zevra Therapeutics has a beta of 1.97, indicating that its stock price is 97% more volatile than the S&P 500. Do insiders & institutionals believe in VCEL or ZVRA? 35.0% of Zevra Therapeutics shares are owned by institutional investors. 5.2% of Vericel shares are owned by insiders. Comparatively, 2.4% of Zevra Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Is VCEL or ZVRA more profitable? Vericel has a net margin of 1.25% compared to Zevra Therapeutics' net margin of -226.78%. Vericel's return on equity of 1.09% beat Zevra Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Vericel1.25% 1.09% 0.73% Zevra Therapeutics -226.78%-201.05%-53.55% Do analysts rate VCEL or ZVRA? Vericel presently has a consensus price target of $61.14, indicating a potential upside of 47.33%. Zevra Therapeutics has a consensus price target of $23.14, indicating a potential upside of 100.20%. Given Zevra Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Zevra Therapeutics is more favorable than Vericel.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vericel 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00Zevra Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 Does the media prefer VCEL or ZVRA? In the previous week, Zevra Therapeutics had 8 more articles in the media than Vericel. MarketBeat recorded 10 mentions for Zevra Therapeutics and 2 mentions for Vericel. Vericel's average media sentiment score of 0.92 beat Zevra Therapeutics' score of 0.73 indicating that Vericel is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vericel 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zevra Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation & earnings, VCEL or ZVRA? Vericel has higher revenue and earnings than Zevra Therapeutics. Zevra Therapeutics is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVericel$237.22M8.81$10.36M$0.031,383.33Zevra Therapeutics$23.61M26.77-$105.51M-$1.90-6.08 SummaryVericel beats Zevra Therapeutics on 9 of the 17 factors compared between the two stocks. Get Zevra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ZVRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZVRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZVRA vs. The Competition Export to ExcelMetricZevra TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$631.55M$2.39B$5.51B$8.96BDividend YieldN/A1.80%5.25%4.02%P/E Ratio-6.089.2628.0520.15Price / Sales26.77771.14438.14127.85Price / CashN/A161.3437.0657.97Price / Book15.624.638.125.62Net Income-$105.51M$31.26M$3.16B$248.50M7 Day Performance22.85%6.81%4.40%5.54%1 Month Performance25.79%4.31%4.09%7.52%1 Year Performance111.14%3.88%34.53%22.06% Zevra Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZVRAZevra Therapeutics2.7477 of 5 stars$11.56+0.1%$23.14+100.2%+157.2%$631.55M$23.61M-6.0820VCELVericel2.9345 of 5 stars$41.79+0.8%$61.14+46.3%-14.4%$2.10B$237.22M1,393.30300AGIOAgios Pharmaceuticals4.0684 of 5 stars$36.06+2.0%$58.60+62.5%-11.9%$2.09B$36.50M3.21390CGONCG Oncology2.3595 of 5 stars$26.90+0.8%$58.67+118.1%-19.0%$2.05B$1.14M-17.8161KNSAKiniksa Pharmaceuticals International3.4296 of 5 stars$27.86+1.5%$38.80+39.3%+37.0%$2.03B$423.24M-111.42220Analyst UpgradeBEAMBeam Therapeutics2.6478 of 5 stars$20.02+0.7%$48.75+143.5%-14.9%$2.01B$63.52M0.00510Gap UpIDYAIDEAYA Biosciences3.4092 of 5 stars$22.09+0.8%$53.42+141.8%-45.7%$1.94B$7M-6.1580News CoverageAnalyst ForecastIRONDisc Medicine3.1623 of 5 stars$54.75+3.0%$96.70+76.6%+11.5%$1.90BN/A0.0030Insider TradeBLTEBelite Bio2.6439 of 5 stars$59.74+5.2%$96.67+61.8%+23.7%$1.89BN/A0.0010Analyst RevisionCNTACentessa Pharmaceuticals2.5803 of 5 stars$14.34+4.3%$27.89+94.6%+50.3%$1.88B$6.85M0.00200HRMYHarmony Biosciences4.8134 of 5 stars$32.09-0.1%$53.63+67.1%+0.6%$1.85B$714.73M12.27200Positive News Related Companies and Tools Related Companies Vericel Alternatives Agios Pharmaceuticals Alternatives CG Oncology Alternatives Kiniksa Pharmaceuticals International Alternatives Beam Therapeutics Alternatives IDEAYA Biosciences Alternatives Disc Medicine Alternatives Belite Bio Alternatives Centessa Pharmaceuticals Alternatives Harmony Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZVRA) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zevra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zevra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
